- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02047825
Upper Limbs Intervention in Multiple Sclerosis
Intervention Focused on Lower Limbs and Functionality in Patients With Multiple Sclerosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The total estimated prevalence rate of multiple sclerosis has been reported to be 83 per 100 000 for the past three decades. It is also higher in northern countries and between females with a male ratio around 2.0. The highest prevalence rates have been estimated for the age group 35-64 years. The estimated European mean annual Multiple Sclerosis incidence rate is 4.3 cases per 100 000.
Multiple sclerosis can cause a variety of symptoms: hypoesthesia, muscle weakness, abnormal muscle spasms, or difficulty moving; difficulties with coordination and balance; dysarthria, dysphagia, visual problems fatigue and acute or chronic pain syndromes, bladder and bowel difficulties,cognitive impairment, or emotional symptomatology. The investigators focus on the benefits of an intervention on dexterity, strength, coordination and functionality.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Granada, Spain, 18071
- Faculty of Health Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients diagnosed with multiple sclerosis.
- Subjects who can complete the assessment battery of tests at the beginning and at the end of the study
Exclusion Criteria:
- Auditive and visual disturbances.
- Cognitive problems.
- Psychiatric pathology.
- Sensorial disturbances.
- Traumatic pathology of the hand.
- Concomitant neurological conditions
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Experimental group
The patients included in this group will receive an intensive intervention based on upper limbs intervention with exercises added to the usual treatment they receive.
|
An 8-week intervention with different exercises will be performed.
This intervention will focus on upper limbs.
The exercises will include plaster of resistance, elastic bands and other exercises.
Other Names:
|
|
Active Comparator: Control group
Patients with multiple sclerosis not included in the intensive intervention.
They receive the usual treatment of occupational and physical therapy.
|
Occupational therapy and physiotherapy, twice a week, as usual.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in manual dexterity
Time Frame: baseline, 8 weeks
|
Changes from baseline to postintervention in manual dexterity assessed by the Purdue Pegboard test and coin rotation task.
The Purdue pegboard test is a timed physical test used to measure manual dexterity.
Test subjects are asked to place small pins into holes in the pegboard using a specific hand and following a specific process.
The coin rotation task consists of rotate the coin during 10 seconds.
|
baseline, 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in apraxia
Time Frame: baseline, 8 weeks
|
Changes in apraxia from baseline to postintervention is going to be measured using the Apraxia Screen of Tulia.
This is a screening test of upper limbs apraxia.
|
baseline, 8 weeks
|
|
Changes in grip strength
Time Frame: baseline, 8 weeks
|
The changes in the grip strength will be measured using a Jamar dynamometer with a standard protocol allowing three attempts on each side.
During each measurement, patients were sitting with their shoulder adducted and elbow flexed to 90°.
The maximum value achieved from all six attempts was used in analyses.
kg/cm2.
|
baseline, 8 weeks
|
|
Change in fatigue
Time Frame: baseline, 8 weeks
|
The fatigue change is going to be measured using the Fatigue Severity Scale, a 9-item scale focus on the severity of fatigue and how much it affects the person's activities and lifestyle in the patients.
|
baseline, 8 weeks
|
|
Upper limb functioning
Time Frame: baseline, 8 weeks
|
The upper limb functioning is going to be measured with the Action Research Arm Test, it is a 19 item measure divided into 4 sub-tests (grasp, grip, pinch, and gross arm movement).
|
baseline, 8 weeks
|
|
Pinch strength
Time Frame: baseline, 8 weeks
|
Pinch strength is going to be measured using a pinch dynamometer.
The participants were asked to perform three repetitions on each side with five seconds rest provided between the measures.
This was performed using the alternating-hands method, which allows rest between repetitions as the examiner records information and provides instructions for the alternate hand.
Three pinchs were evaluated: lateral, distal and tripod pinch
|
baseline, 8 weeks
|
|
Tapping speed
Time Frame: baseline, 8 weeks
|
The tapping speed will be measured with the finger tapping test.
|
baseline, 8 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of life
Time Frame: Baseline, 8 weeks
|
Quality of life is going to be measured using a self-reported questionnaire, the short-form Health Survey, SF-36
|
Baseline, 8 weeks
|
|
Goals achievement
Time Frame: baseline, 8 weeks
|
The achievement of the goals of the intervention will be measured with the Goal Attainment Scale, a method of scoring the extent to which patient's individual goals are achieved in the course of intervention.
|
baseline, 8 weeks
|
|
Functionality
Time Frame: baseline, 8 weeks
|
Functionality will be measured with the Functional Independence Measure, a questionnaire.
This is the most widely accepted functional assessment measure in use in the rehabilitation community
|
baseline, 8 weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DF0048UG
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Upper limbs intervention
-
IRCCS San Camillo, Venezia, ItalyUniversità Politecnica delle Marche; University of GenovaUnknown
-
National Taiwan University HospitalRecruiting
-
Universidade Federal do Rio Grande do NorteRecruitingStroke | Quality of Life | Chest Wall DisorderBrazil
-
University of Sao PauloCompleted
-
University Hospital, GrenobleRecruitingRenal Insufficiency | Arteriopathy Upper Limb | Digital PressureFrance
-
Hospital de Clinicas de Porto AlegreAssociação Fundo de Incentivo à PesquisaCompletedPulmonary Disease, Chronic ObstructiveBrazil
-
Cyprus University of TechnologyThe Cyprus Foundation for Muscular Dystrophy ResearchCompletedMultiple SclerosisCyprus
-
University of PisaAzienda Ospedaliero, Universitaria Pisana; Fondazione Don Carlo Gnocchi Onlus; Ospedale Policlinico San Martino and other collaboratorsNot yet recruiting
-
Riphah International UniversityCompletedPulmonary Arterial Hypertension (PAH)Pakistan
-
Centre Antoine LacassagneThuasneRecruitingNon-metastatic Breast CancerFrance